Patents by Inventor Stefan Pflanz

Stefan Pflanz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140212412
    Abstract: Methods for treating fibrotic disease, such as idiopathic pulmonary fibrosis and scleroderma, with antagonists of IL-33 are disclosed.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 31, 2014
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: ANDREW L. RANKIN, STEFAN PFLANZ, JOHN MUMM
  • Publication number: 20120263709
    Abstract: Methods for treating fibrotic disease, such as idiopathic pulmonary fibrosis and scleroderma, with antagonists of IL-33 are disclosed.
    Type: Application
    Filed: September 1, 2010
    Publication date: October 18, 2012
    Applicant: SCHERING CORPORATION
    Inventors: Andrew L. Rankin, Stefan Pflanz, John Mumm
  • Patent number: 7964707
    Abstract: The invention relates to a humanized monoclonal antibody or fragment thereof which specifically binds to human interlukin-2 (IL2), whereby said humanized monoclonal antibody neutralizes the activity of human IL2 by binding to the human IL2 prior to, during, and/or subsequent to the binding of the human IL2 to the human IL2-receptor, and wherein the light chain variable region of the humanized monoclonal antibody comprises in its second framework region the contiguous amino acid sequence KAPKA at amino acid positions 42-46.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: June 21, 2011
    Assignee: Micromet AG
    Inventors: Patrick Bäuerle, John Lumsden, Stefan Pflanz, Tobias Raum, Jörg Volkland
  • Publication number: 20080317746
    Abstract: The invention relates to a humanized monoclonal antibody or fragment thereof which specifically binds to human interleukin-2 (IL2), wherein said humanized monoclonal antibody neutralizes the activity of human IL2 by binding to said human IL2 prior to, during, and/or subsequent to the binding of said human IL2 to the human IL2-receptor, and wherein the light chain variable region of said humanized monoclonal antibody comprises in its second framework region the contiguous amino acid sequence KAPKA at amino acid positions 42-46.
    Type: Application
    Filed: May 31, 2006
    Publication date: December 25, 2008
    Applicant: MICROMET AG
    Inventors: Patrick Bauerle, John Lumsden, Stefan Pflanz, Tobias Raum, Jorg Volkland
  • Publication number: 20050214296
    Abstract: Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders. Also provided are methods of administering agonists or antagonists of IL-27 and IL-27 receptor.
    Type: Application
    Filed: February 15, 2005
    Publication date: September 29, 2005
    Applicant: Schering Corporation
    Inventors: Robert Kastelein, Terrill McClanahan, Stefan Pflanz